Literature DB >> 10890963

Gasless endoscopic anterior lumbar interbody fusion utilizing the B. E.R.G. approach.

J S Thalgott1, A K Chin, J A Ameriks, F T Jordan, M D Daubs, J M Giuffre, K Fritts, M Timlin.   

Abstract

BACKGROUND: Several authors have reported success using a gas-mediated transperitoneal approach for lumbar interbody fusion. However, this approach has not been shown to reliably and predictably address segments above L4-5.
METHODS: The B.E.R.G. approach was attempted in 202 patients who required anterior lumbar interbody fusion (ALIF). Of those, 168 were completed successfully without conversion to an open procedure. The anterior retroperitoneal approach required no gas insufflation. The gasless environment allowed for the use of standard anterior instrumentation and a variety of fusion grafts and devices.
RESULTS: Mean hospital stay was 1.95 days, with 73% of patients discharged in <47 h following surgery. Clinical results from the first 50 patients, with a minimum 2-year follow-up, include a 92% fusion rate and 78% of patients reporting significant pain relief of greater than 50%.
CONCLUSIONS: The B.E.R.G. approach offers significant technical advantages over the standard gas-mediated transperitoneal approach for ALIF. The clinical results are similar to those reported for open approaches and the gas-mediated transperitoneal approach.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10890963     DOI: 10.1007/s004640020086

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  2 in total

1.  "Does size matter?"A comparison of balloon-assisted less-invasive vs conventional retroperitoneal approach for anterior lumbar interbody fusion.

Authors:  Najma Farooq; Michael P Grevitt
Journal:  Eur Spine J       Date:  2004-06-26       Impact factor: 3.134

2.  Laparoscopically assisted retroperitoneal spinal surgery.

Authors:  Joseph P Regan; Richard P Cattey; Lyle G Henry; Stephen Robbins
Journal:  JSLS       Date:  2006 Oct-Dec       Impact factor: 2.172

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.